Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis
Journal of Digestive Diseases, 03/27/2012Tong JL et al.
Once–daily (OD) mesalamine is as effective and has a comparable safety profile as multiple–daily (MD) regimens for the maintenance treatment of ulcerative colitis (UC), and is even more effective for inducing remission in active UC.
Electronic databases up to July 2011 were searched for related studies evaluating the efficacy of OD vs MD for treatment of UC.
Only randomized controlled trials (RCTs) were considered eligible.
Remission rates or relapse rates were analyzed using intention-to-treat (ITT) and per-protocol (PP) analysis.
Pooled relative risk (RR) and 95% confidence interval (CI) were calculated.
Publication bias was assessed with a funnel plot.
Overall 10 RCTs including 9 full-text manuscripts and one abstract met the inclusion criteria.
OD dosing of mesalamine was shown to be as effective as MD dosing for the maintenance of clinical remission in patients with quiescent UC (RR = 1.00, 95% CI 0.89–1.12) by ITT analysis.
For active UC, a mild but significant benefit was achieved by OD dosing compared with MD dosing (RR = 0.80, 95% CI 0.64–0.99).
Total adverse events were similar using OD and MD mesalamine in quiescent UC (RR = 1.06, 95% CI 0.93–1.20).
Compliance with OD was slightly better than with MD (RR = 0.92, 95% CI 0.82–1.03).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.